Mostrar el registro sencillo del ítem

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHALOUNI, Mathieu
dc.contributor.authorLOUBET, Paul
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLHOMME, Edouard
dc.contributor.authorNINOVE, Laetitia
dc.contributor.authorBARROU, Benoit
dc.contributor.authorBLAY, Jean-Yves
dc.contributor.authorHOURMANT, Maryvonne
dc.contributor.authorDE SEZE, Jérome
dc.contributor.authorLAVILLE, Martine
dc.contributor.authorLAVIOLLE, Bruno
dc.contributor.authorLELIÈVRE, Jean-Daniel
dc.contributor.authorMOREL, Jacques
dc.contributor.authorQUOC, Stéphanie Nguyen
dc.contributor.authorSPANO, Jean-Philippe
dc.contributor.authorTERRIER, Benjamin
dc.contributor.authorTHIEBAUT, Anne
dc.contributor.authorVIALLARD, Jean-Francois
dc.contributor.authorVRTOVSNIK, François
dc.contributor.authorCIRCOSTA, Sophie
dc.contributor.authorBARQUIN, Aude
dc.contributor.authorGHARIB, Mariam
dc.contributor.authorTARTOUR, Eric
dc.contributor.authorPARFAIT, Béatrice
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorMEYER, Laurence
dc.contributor.authorDE LAMBALLERIE, Xavier
dc.contributor.authorLAUNAY, Odile
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.date.accessioned2024-10-29T12:13:25Z
dc.date.available2024-10-29T12:13:25Z
dc.date.issued2024-09-27
dc.identifier.issn1471-2334en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202948
dc.description.abstractEnWe assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection over the following six months in specific populations. ANRS0001SCOV-POPART is a French nationwide multicenter prospective observational cohort study assessing the immune response to Covid-19 vaccines routinely administered to 11 subgroups of patients with chronic disease and a control group. Participants from the ANRS0001S COV-POPART were included if they received at least two doses of Covid-19 vaccine for the primary vaccine course, had measurements of anti-Spike, anti-receptor binding domain (RBD) IgG-specific or neutralizing antibodies one month after the end of the primary vaccine course, without being infected by SARS-CoV-2 before the measurement. SARS-CoV-2 infections defined by a positive PCR/antigenic test or seroconversion to detectable anti nucleocapsid antibodies were evaluated until the first COVID-19 booster injection. Cox proportional hazards models taking into account interval-censored data were implemented to estimate the association between each antibody level and the risk of SARS-CoV-2 infection. Predictive performances were evaluated by the area under the receiving operating characteristic curve (AUROC). Two thousand five hundred seventy adults from a specific population and 1,123 from the control group were included. The cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement were 6.0% 95% confidence interval: [5.0; 7.9] and 10.1% 95% confidence interval: [8.3; 11.9], respectively. Higher levels of anti-Spike IgG antibody were associated with a lower risk of SARS-CoV-2 infections in the control group, but not in the specific populations. Among the specific populations, AUROC were 74.5%, 74.9%, and 72.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. AUROC were superior in the specific populations, 82.0%, 81.2%, and 81.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. Vaccine-induced antibody response after the primary course of Covid-19 infection only moderately discriminated between participants developing a SARS-CoV-2 infection during the Omicron wave. NCT04824651 (first posted: 2021-04-01).
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enHumans
dc.subject.enCOVID-19
dc.subject.enMale
dc.subject.enFemale
dc.subject.enMiddle Aged
dc.subject.enAntibodies
dc.subject.enViral
dc.subject.enCOVID-19 Vaccines
dc.subject.enSARS-CoV-2
dc.subject.enProspective Studies
dc.subject.enAntibodies
dc.subject.enNeutralizing
dc.subject.enAged
dc.subject.enAdult
dc.subject.enFrance
dc.subject.enImmunoglobulin G
dc.subject.enBiomarkers
dc.subject.enSpike Glycoprotein
dc.subject.enCoronavirus
dc.subject.enCohort Studies
dc.subject.enImmunity
dc.subject.enHumoral
dc.title.enAssociation between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
dc.title.alternativeBMC Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s12879-024-09861-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39333909en_US
bordeaux.journalBMC Infectious Diseasesen_US
bordeaux.page1049en_US
bordeaux.volume24en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Infectious%20Diseases&rft.date=2024-09-27&rft.volume=24&rft.issue=1&rft.spage=1049&rft.epage=1049&rft.eissn=1471-2334&rft.issn=1471-2334&rft.au=CHALOUNI,%20Mathieu&LOUBET,%20Paul&LHOMME,%20Edouard&NINOVE,%20Laetitia&BARROU,%20Benoit&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_BMCID_2024_Chalouni.pdf
Tamaño:
1.509Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem